1) Small molecular inhibitors. The Stoyanova lab utilizes multiple approaches to develop new therapeutic strategies for late-stage cancers including the discovery and testing of new therapeutic targets and new small molecule inhibitors. Currently the lab focuses on prostate, breast, lung cancer, and neuroblastoma.
2) Small molecular inhibitor screening. The Stoyanova lab utilizes High-Throughput Screening (HTS) to identify new and selective small molecule inhibitors for metastatic epithelial cancers.
3) Antibody-based therapies for advanced prostate, breast, lung, and other epithelial cancers. The Stoyanova lab develops and tests antibody-based strategies as targeted therapies. We also construct new antibody-drug conjugates as a therapeutic strategy to deliver toxic agents to the tumor sites.